Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
- Authors: Poskakalova A.E.1, Nasonova S.N.1, Zhirov I.V.1,2, Tereshchenko S.N.1
-
Affiliations:
- Chazov National Medical Research Center of Cardiology
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 25, No 4 (2023): Endocrinology
- Pages: 259-265
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/131665
- DOI: https://doi.org/10.26442/20751753.2023.4.202263
- ID: 131665
Cite item
Full Text
Abstract
Background. Chronic heart failure (CHF) is an immediate cardiological problem. At the same time, acute decompensated heart failure (ADHF) is associated with an extremely unfavorable prognosis and low survival of patients.
Aim. To evaluate the safety of sodium-glucose cotransporter-2 inhibitor dapagliflozin early administration in patients with ADHF with a reduced left ventricular ejection fraction (LVEF) regardless of type 2 diabetes mellitus (diabetes).
Materials and methods. We used standard CHF therapy and intravenous diuretic therapy in combination with 10 mg dapagliflozin in 43 patients with NYHA class II–IV ADHF. The study mainly included 39 (90.7%) male patients, the mean age was 60±12 years (56–63), diabetes was in 14 (32.6%) patients. Dapagliflozin was prescribed by a mean of 2 days (1–3) from admission to the hospital. The parameters were analyzed at the time of inclusion in the study and when CHF compensation was achieved.
Results. The median of the length of hospital stay was 7 days (6–10). LVEF significantly increased during hospitalization from 27±6 to 30±7% (p<0.001) and the level of NT-proBNP decreased: from 3700 pg/ml (1745–5331) to 1366 pg/ml (1025–2878); p=0.007. A decrease in the marker was observed in 90% of patients. Hypotension (decrease in systolic blood pressure – BP less than 90 mmHg) was observed in 10 (23.3%) patients. A statistically significant decrease in BP was found: systolic and diastolic BP on admission was 114 mmHg (100–126) and 70 mmHg (70–80), respectively, when CHF compensation was achieved – 110 mmHg (98–120) and 70 mmHg (61–78); p=0.047 and p=0.013, respectively. The increase in hematocrit during hospitalization was also statistically significant – from 43.5±3.6 to 46.1±4.9% (p<0.001) and this was found in 67% of patients. A total of 4 (9.3%) patients had acute renal injury (decrease in estimated glomerular filtration rate – GFR by 25% or more). At the same time, there was no decrease in GFR of less than 15 ml/min/1.73 m2. There was no statistically significant decrease in GFR and an increase in creatinine levels during hospitalization (p=0.214 and 0.173, respectively). Urinary tract infections were observed in 1 (2.3%) patient, transient hypoglycemia – in 2 (4.7%) patients, which did not lead to the discontinuation of dapagliflozin. Diabetic ketoacidosis, allergic reactions, syncope, lower extremity amputations were not observed in patients taking dapagliflozin.
Conclusion. It can be concluded that dapagliflozin has a favorable safety profile when used in patients with ADHF, regardless of the presence or absence of diabetes.
Full Text
##article.viewOnOriginalSite##About the authors
Anastasiya E. Poskakalova
Chazov National Medical Research Center of Cardiology
Email: anastasiyalapteva95@gmail.com
ORCID iD: 0000-0002-9260-9520
Graduate Student
Russian Federation, MoscowSvetlana N. Nasonova
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0002-0920-7417
Cand. Sci. (Med.)
Russian Federation, MoscowIgor V. Zhirov
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
Author for correspondence.
Email: izhirov@mail.ru
ORCID iD: 0000-0002-4066-2661
D. Sci. (Med.)
Russian Federation, Moscow; MoscowSergey N. Tereshchenko
Chazov National Medical Research Center of Cardiology
Email: izhirov@mail.ru
ORCID iD: 0000-0001-9234-6129
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: 10.1093/eurheartj/ehab368
- Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021;61(4):4-14 [Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. doi: 10.18087/cardio.2021.4.n1628
- Chioncel O, Mebazaa A, Maggioni AP, et al. ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338-52. doi: 10.1002/ejhf.1492
- Chioncel O, Mebazaa A, Harjola VP, et al. ESC Heart Failure Long-Term Registry Investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(10):1242-54. doi: 10.1002/ejhf.890
- Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713-22. doi: 10.1002/ejhf.1713
- Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail. 2021;23(5):826-34. doi: 10.1002/ejhf.2137
- Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-74. doi: 10.1038/s41591-021-01659-1
- Tamaki S, Yamada T, Watanabe T, et al. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. Circ Heart Fail. 2021;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048
- Schulze PC, Bogoviku J, Westphal J, et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation. 2022;146(4):289-98. doi: 10.1161/CIRCULATIONAHA.122.059038
- Szarek M, Bhatt DL, Steg PG, et al. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Ann Intern Med. 2021;174(8):1065-72. doi: 10.7326/M21-0651
- Salah HM, Al'Aref SJ, Khan MS, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):20. doi: 10.1186/s12933-022-01455-2
- Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Am Heart J. 2021;232:116-24. doi: 10.1016/j.ahj.2020.10.071
- Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure – Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68). ClinicalTrials.gov. April 27, 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT04363697. Accessed: 06.12.2021.
- Packer M, Anker SD, Butler J, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. J Am Coll Cardiol. 2021;77(11):1381-92. doi: 10.1016/j.jacc.2021.01.033
- Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326-36. doi: 10.1161/CIRCULATIONAHA.120.051783
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303